CDMO Samsung Biologics expanded its collaboration with LigaChem Biosciences (LCB) to provide antibody-drug conjugate (ADC) services. Samsung will support a series of LigaChem’s ADC programs at ...
INCHEON, South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung ... collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services. Samsung Biologics Logo ...
Samsung Biologics will support a series of LigaChem Biosciences' ADC programs at Samsung Biologics' new dedicated ADC facility. The two companies have already been collaborating on ADC programs ...
Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise INCHEON, South Korea, Jan. 8, 2025 /PRNewswire/ -- Samsung ...
207940.KS), a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate ...
Samsung Biologics, a global contract development and manufacturing organization (CDMO), announced to extend collaboration with LigaChem Biosciences to provide antibody-drug conjugate (ADC) services.
INCHEON, South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with ...
Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise "The latest collaboration will further strengthen Samsung ...
LigaChem Biosciences is a biotech pioneering research and development of ADC candidates. "The latest collaboration will further strengthen Samsung Biologics' capabilities across all stages of ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback